http://www.nitrc.org/forum/forum.php?forum_id=6355 <table border="0" width="100%"><tr><td align="left"/></tr></table> <p><b>Combining escitalopram and cognitive-behavioural therapy for social anxiety disorder: randomised controlled fMRI trial.</b></p> <p>Br J Psychiatry. 2016 Jun 23;</p> <p>Authors: Gingnell M, Frick A, Engman J, Alaie I, Björkstrand J, Faria V, Carlbring P, Andersson G, Reis M, Larsson EM, Wahlstedt K, Fredrikson M, Furmark T</p> <p>Abstract<br/> BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) and cognitive-behavioural therapy (CBT) are often used concomitantly to treat social anxiety disorder (SAD), but few studies have examined the effect of this combination.<br/> AIMS: To evaluate whether adding escitalopram to internet-delivered CBT (ICBT) improves clinical outcome and alters brain reactivity and connectivity in SAD.<br/> METHOD: Double-blind, randomised, placebo-controlled neuroimaging trial of ICBT combined either with escitalopram (n = 24) or placebo (n = 24), including a 15-month clinical follow-up (trial registration: ISRCTN24929928).<br/> RESULTS: Escitalopram+ICBT, relative to placebo+ICBT, resulted in significantly more clinical responders, larger reductions in anticipatory speech state anxiety at post-treatment and larger reductions in social anxiety symptom severity at 15-month follow-up and at a trend-level (P = 0.09) at post-treatment. Right amygdala reactivity to emotional faces also decreased more in the escitalopram+ICBT combination relative to placebo+ICBT, and in treatment responders relative to non-responders.<br/> CONCLUSIONS: Adding escitalopram improves the outcome of ICBT for SAD and decreased amygdala reactivity is important for anxiolytic treatment response.<br/> </p><p>PMID: 27340112 [PubMed - as supplied by publisher]</p> en-us Copyright 2000-2026 NITRC OSI Tue, 05 May 2026 4:12:34 GMT http://blogs.law.harvard.edu/tech/rss NITRC RSS generator